-
Product Insights
New![]()
Net Present Value Model: Immatics NV’s IMA-201
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Immatics NV’s IMA-203
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Immatics Biotechnologies GmbH – Company Profile
Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer, and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer....
Add to Basket -
Product Insights
New![]()
Net Present Value Model: IO Biotech Inc’s (IO-102 + IO-103)
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LHF-535 in Arenaviridae Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LHF-535 in Arenaviridae InfectionsDrug Details:LHF-535 is under development for the treatment of arenaviridae infection and lassa...
-
Track & Monitor
New![]()
Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Hidradenitis Suppurativa Drug Details: Amlitelimab (KY-1005) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RNK-05047 in Diffuse Large B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RNK-05047 in Diffuse Large B-Cell Lymphoma Drug Details:RNK-05047 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dihydroergotamine Mesylate (Dhe) in Cluster Headache Syndrome (Cluster Headache)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Dihydroergotamine Mesylate (Dhe) in Cluster Headache Syndrome (Cluster Headache) Drug Details:Dihydroergotamine mesylate is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Gastrointestinal Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Gastrointestinal TumorDrug Details:ARB-202 is under development for the treatment of refractory pancreatic cancer, refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Solid Tumor Drug Details:IMA-203CD8 is under development for the treatment of multiple solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Uveal Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Uveal Melanoma Drug Details:IMA-203CD8 is under development for the treatment of multiple solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine For Chronic Lymphocytic Leukaemia And Solid Tumor in Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Vaccine For Chronic Lymphocytic Leukaemia And Solid Tumor in Chronic Lymphocytic Leukemia (CLL) Drug Details:Peptide vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Head And Neck Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Head And Neck Cancer Drug Details:IMA-203CD8 is under development for the treatment of multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Hepatocellular Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Hepatocellular Carcinoma Drug Details:IMA-203CD8 is under development for the treatment of multiple solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Synovial Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Synovial SarcomaDrug Details:IMA-203CD8 is under development for the treatment of multiple solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-950 in Low-Grade Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IMA-950 in Low-Grade GliomaDrug Details:IMA-950 is under development for the treatment of relapsing glioblastoma, glioma including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Diffuse Large B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Fenebrutinib in Diffuse Large B-Cell Lymphoma Drug Details:Fenebrutinib (GDC-0853, RG-7845) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XT-150 in Osteoarthritis Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.XT-150 in Osteoarthritis Pain Drug Details:XT-150 is under development for the treatment of neuropathic pain, multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-19 in B-Cell Chronic Lymphocytic Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IM-19 in B-Cell Chronic Lymphocytic LeukemiaDrug Details: IM-19 is under development for the treatment of relapsed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.